Table 4.
Reported cases of locally advanced and metastatic non-melanoma skin cancers treated with nivolumab.
| Number of Patients | Patient Data (Sex, Age) |
Diagnosis | Nivolumab Regimen | Outcome | Additional Information | Ref. |
|---|---|---|---|---|---|---|
| 3 | M, 65 y; M, 66 y; F, 61 y |
2 m-cSCCs; 1 m-BCC (basosquamous cancer) |
3 mg/kg IV every 2 weeks | 1 PR; 2 SD |
/ | Borradori et al., 2016 [56] |
| 1 | F, age not specified | m-cSCC | 3 mg/kg IV every 2 weeks | PR | / | Tran et al., 2017 [53] |
| 1 | F, 69 y | m-cSCC | Not specified | PR | Kidney transplant recipient; allograft preserved | Kittai et al., 2017 [95] |
| 1 | M, 74 y | la-cSCC | Nivolumab IV every 2 weeks + cetuximab every week | CR | / | Chen et al., 2017 [86] |
| 3 | M, 66 y; M, 72 y; F, 81 y |
m-cSCCs | 3 mg/kg IV every 2 weeks | 3 PR (including one near-CR) | / | Blum et al., 2018 [85] |
| 1 | M, 50 y | m-cSCC | 3 mg/kg IV every 2 weeks | PR | Kidney transplant recipient; allograft rejection | Goldman et al., 2018 [87] |
| 6 (in a cohort of 26 patients) | Data for the entire cohort: 19 M, 7 F; median age: 64.5 y |
Data for the entire cohort: 5 la-cSCCs; 21 m-cSCCs |
Not specified | RR 33.3% | The entire cohort included 26 patients treated with cemiplimab (13), pembrolizumab (7) and nivolumab (6) | In et al., 2020 [42] |
| 1 | M, 58 y | m-BCC | 240 mg IV every 2 weeks |
PR (near-CR) | / | Ikeda et al., 2016 [88] |
| 1 | M, 42 y | m-MCC | 3 mg/kg IV every 2 weeks | PR | / | Mantripragada et al., 2015 [89] |
| 1 | M, 80 y | m-MCC | 3 mg/kg IV every 2 weeks | PR | / | Walocko et al., 2016 [90] |
| 25 | Advanced MCCs | 240 mg IV every 2 weeks |
3 CR (14%); 12 PR (55%); 4 SD (18%); 3 PD (14%) |
CheckMate 358 study (phase I/II trial) | Topalian et al., 2017 [93] | |
| 1 | m-MCC | 3 mg/kg IV every month | PR | Kidney transplant recipient; allograft function preserved | Singh et al., 2019 [91] |
Note: Abbreviations: M (male); F (female); y (years); m-BCC (metastatic basal cell carcinoma); la-cSCC (locally advanced cutaneous squamous cell carcinoma); m-cSCC (metastatic cutaneous squamous cell carcinoma); m-MCC (metastatic Merkel cell carcinoma); IV (intravenously); CR (complete response); PR (partial response); SD (stable disease); PD (progressive disease), RR (response rate).